ES2549551T1 - Método de aumentar la dureza y la rigidez ósea y de reducir las fracturas - Google Patents

Método de aumentar la dureza y la rigidez ósea y de reducir las fracturas Download PDF

Info

Publication number
ES2549551T1
ES2549551T1 ES15152726.4T ES15152726T ES2549551T1 ES 2549551 T1 ES2549551 T1 ES 2549551T1 ES 15152726 T ES15152726 T ES 15152726T ES 2549551 T1 ES2549551 T1 ES 2549551T1
Authority
ES
Spain
Prior art keywords
stiffness
increasing bone
bone hardness
reducing fractures
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES15152726.4T
Other languages
English (en)
Other versions
ES2549551T3 (es
Inventor
Janet M Hock
Gregory A Gaich
Willard H Dere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2549551(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of ES2549551T1 publication Critical patent/ES2549551T1/es
Application granted granted Critical
Publication of ES2549551T3 publication Critical patent/ES2549551T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

PTH(1-34) humana para su uso en un metodo para la reducción de la incidencia y/o gravedad de fractura, en un hombre con riesgo de padecer o con osteoporosis, mediante la administración de PTH(1-34) por inyección subcutánea de una dosis de menos de 1 mg/kg/dia.

Claims (1)

  1. imagen1
ES15152726.4T 1998-08-19 1999-08-19 Método para aumentar la tenacidad ósea y la rigidez y reducir las fracturas Expired - Lifetime ES2549551T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US97151P 1998-08-19
US9974698P 1998-09-10 1998-09-10
US99746P 1998-09-10

Publications (2)

Publication Number Publication Date
ES2549551T1 true ES2549551T1 (es) 2015-10-29
ES2549551T3 ES2549551T3 (es) 2017-11-27

Family

ID=26792729

Family Applications (4)

Application Number Title Priority Date Filing Date
ES10180447.4T Expired - Lifetime ES2621653T3 (es) 1998-08-19 1999-08-19 Método para aumentar la tenacidad ósea y la rigidez y reducir las fracturas
ES06027055T Expired - Lifetime ES2393200T3 (es) 1998-08-19 1999-08-19 hPTH(1-34) para uso en la prevención o reducción de la incidencia o gravedad de fractura vertebral y/o no vertebral en un hombre
ES15152726.4T Expired - Lifetime ES2549551T3 (es) 1998-08-19 1999-08-19 Método para aumentar la tenacidad ósea y la rigidez y reducir las fracturas
ES99942350T Expired - Lifetime ES2190244T3 (es) 1998-08-19 1999-08-19 Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES10180447.4T Expired - Lifetime ES2621653T3 (es) 1998-08-19 1999-08-19 Método para aumentar la tenacidad ósea y la rigidez y reducir las fracturas
ES06027055T Expired - Lifetime ES2393200T3 (es) 1998-08-19 1999-08-19 hPTH(1-34) para uso en la prevención o reducción de la incidencia o gravedad de fractura vertebral y/o no vertebral en un hombre

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99942350T Expired - Lifetime ES2190244T3 (es) 1998-08-19 1999-08-19 Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.

Country Status (33)

Country Link
US (2) US6977077B1 (es)
EP (3) EP2907522B1 (es)
JP (5) JP2002523375A (es)
KR (1) KR100454207B1 (es)
CN (1) CN1205997C (es)
AR (1) AR033639A1 (es)
AT (1) ATE231000T1 (es)
AU (1) AU746277B2 (es)
BR (1) BR9909445A (es)
CA (1) CA2325371C (es)
CO (1) CO5130020A1 (es)
CY (2) CY1113343T1 (es)
CZ (1) CZ301017B6 (es)
DE (2) DE69904918T2 (es)
DK (4) DK1769804T3 (es)
DZ (1) DZ2873A1 (es)
EA (1) EA003362B1 (es)
ES (4) ES2621653T3 (es)
HK (3) HK1030545A1 (es)
HR (1) HRP20000755A2 (es)
HU (2) HU1200430D0 (es)
ID (1) ID29039A (es)
IL (2) IL138829A0 (es)
MY (1) MY129227A (es)
NO (2) NO323984B1 (es)
NZ (1) NZ507056A (es)
PE (1) PE20001089A1 (es)
PL (1) PL201688B1 (es)
PT (4) PT2907522T (es)
TR (1) TR200003455T2 (es)
TW (1) TW576747B (es)
UA (1) UA72205C2 (es)
WO (1) WO2000010596A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
WO2001022093A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
US7015195B2 (en) * 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
JP2007505883A (ja) * 2003-09-19 2007-03-15 ファイザー・プロダクツ・インク ２−アルキリデン−１９−ノル−ビタミンｄ誘導体及び副甲状腺ホルモンの組合せを含んでなる医薬組成物及び方法
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
JP5007427B2 (ja) 2004-05-13 2012-08-22 アルザ コーポレイション 副甲状腺ホルモン剤の経皮送達のための装置および方法
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
CA2608016A1 (en) * 2005-05-11 2006-11-23 Unigene Laboratories, Inc. Improving bone formation and preservation by surgically inducing an increase in osteoblast activity coupled with the effect of administering pthrp or cgrp
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
ES2381639T3 (es) 2007-04-13 2012-05-30 Kuros Biosurgery Ag Sellante polimérico para tejidos
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
EP2227263A2 (en) 2007-12-28 2010-09-15 Kuros Biosurgery AG Pdgf fusion proteins incorporated into fibrin foams
KR102424644B1 (ko) 2009-09-09 2022-07-25 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
KR101787956B1 (ko) 2011-06-07 2017-10-18 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP6815407B2 (ja) * 2016-02-01 2021-01-20 イーライ リリー アンド カンパニー 副甲状腺ホルモン−抗ｒａｎｋｌ抗体融合化合物
JP2020506926A (ja) * 2017-02-01 2020-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 副甲状腺ホルモンと変性椎間板疾患の再生
EP3685849A4 (en) * 2017-09-22 2021-12-22 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY
WO2020090174A1 (ja) 2018-10-29 2020-05-07 旭化成ファーマ株式会社 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法
JP2022543871A (ja) 2019-08-09 2022-10-14 フラッグシップ・パイオニアリング・イノベーションズ・ブイアイ，エルエルシー 副甲状腺ホルモン受容体（ｐｔｈｒ１）の調節剤
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
EP1283035A3 (en) * 1994-12-22 2003-03-19 AstraZeneca AB Therapeutic preparation for inhalation containing parathyroid hormone
JPH08310965A (ja) 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
EP1005359B1 (en) * 1997-09-09 2005-06-15 F. Hoffmann-La Roche Ag FRACTURE HEALING USING PTHrP ANALOGS
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
IL138829A (en) 2011-01-31
PE20001089A1 (es) 2000-11-04
NZ507056A (en) 2003-10-31
NO20005947L (no) 2000-11-24
HK1102496A1 (en) 2007-11-23
HK1212602A1 (zh) 2016-06-17
TW576747B (en) 2004-02-21
CY1113343T1 (el) 2016-06-22
TR200003455T2 (tr) 2001-06-21
US6977077B1 (en) 2005-12-20
HU1200430D0 (hu) 2001-11-28
WO2000010596A1 (en) 2000-03-02
UA72205C2 (uk) 2005-02-15
EP2907522A1 (en) 2015-08-19
CZ20004134A3 (cs) 2001-08-15
EP1059933B1 (en) 2003-01-15
MY129227A (en) 2007-03-30
ES2621653T3 (es) 2017-07-04
HK1030545A1 (en) 2001-05-11
ATE231000T1 (de) 2003-02-15
PT2266598T (pt) 2017-05-02
JP2014139220A (ja) 2014-07-31
DZ2873A1 (fr) 2003-12-15
EP2266598B1 (en) 2017-02-22
DE69904918D1 (de) 2003-02-20
CA2325371C (en) 2004-08-17
PL343595A1 (en) 2001-08-27
CA2325371A1 (en) 2000-03-02
PT2907522T (pt) 2017-10-23
NO20005947D0 (no) 2000-11-24
EP1059933A1 (en) 2000-12-20
ID29039A (id) 2001-07-26
KR100454207B1 (ko) 2004-10-26
US7163684B2 (en) 2007-01-16
DK2907522T3 (en) 2017-10-23
JP2011021035A (ja) 2011-02-03
CN1205997C (zh) 2005-06-15
PT1059933E (pt) 2003-06-30
EP2266598A1 (en) 2010-12-29
CZ301017B6 (cs) 2009-10-14
HUP0101594A3 (en) 2002-01-28
HUP0101594A2 (hu) 2001-11-28
AU746277B2 (en) 2002-04-18
AR033639A1 (es) 2004-01-07
DE69904918T2 (de) 2003-11-13
US20050197294A1 (en) 2005-09-08
JP2015028065A (ja) 2015-02-12
DK2266598T3 (en) 2017-05-15
EP2907522B1 (en) 2017-08-02
DE15152726T1 (de) 2015-12-10
CY1119552T1 (el) 2018-03-07
EA200001015A1 (ru) 2001-02-26
NO20072983L (no) 2000-11-24
KR20010072763A (ko) 2001-07-31
JP6177718B2 (ja) 2017-08-09
JP2017190332A (ja) 2017-10-19
DK2907522T1 (da) 2015-10-19
DK1769804T3 (da) 2012-10-15
HU230697B1 (hu) 2017-09-28
ES2190244T3 (es) 2003-07-16
ES2549551T3 (es) 2017-11-27
ES2393200T3 (es) 2012-12-19
AU5575099A (en) 2000-03-14
PT1769804E (pt) 2012-11-13
EA003362B1 (ru) 2003-04-24
BR9909445A (pt) 2000-12-12
CO5130020A1 (es) 2002-02-27
DK1059933T3 (da) 2003-04-07
NO323984B1 (no) 2007-07-30
JP2002523375A (ja) 2002-07-30
HRP20000755A2 (en) 2001-02-28
CN1308545A (zh) 2001-08-15
IL138829A0 (en) 2001-10-31
PL201688B1 (pl) 2009-04-30

Similar Documents

Publication Publication Date Title
ES2549551T1 (es) Método de aumentar la dureza y la rigidez ósea y de reducir las fracturas
EP1205154A3 (en) Osteosynthesis plating apparatus and method with extension plate
BRPI0408807A (pt) sistema de fixação de fratura de osso com suporte de superfìcie articular e subcondral
SE9500566L (sv) L-platta
BR0312947A (pt) terapias para insuficiência renal empregando-se interferon-beta
EP1713410A4 (en) SYSTEM FOR STABILIZING FRACTURES OF CONVEX TUBE BONE SURFACES WITH SUBCHONDRIAL SUPPORT STRUCTURE
AR022368A1 (es) Procedimiento para administrar peptidos insulinotropicos
BR9508322A (pt) Uso de quitosan e de um polissacarídeo imobilizado no mesmo processo para estimular e/ou acelerar regeneração de tecido rígido e implante destinado para integração em tecido rígido
ES2075125T3 (es) Tornillo como medio auxiliar de osteosintesis.
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
ATE148328T1 (de) Knochenchirurgische haltevorrichtung
DE69918848D1 (de) Vorderseitenplatte für lendenwirbel und positionierwerkzeug dafür
WO2004045455A3 (en) Deformable bone plates
ECSP055739A (es) Anticuerpos de neutralización contra gdf-8, y sus usos
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
ZA9428B (en) Use of lamotrigine for the treatment of Parkinson's Disease and Parkinsonian Syndromes
EP1104259A4 (en) BONE FIXING DEVICE AND METHOD
NO20040598L (no) 5-CNAC som oralt avleveringsmiddel for paratyreoidhormonfragmenter.
ATE543451T1 (de) Bioabsorbierbare, osteogenetische knochenplatte
BR0314362A (pt) Método para previnir ou reduzir fraturas secundárias após fratura de quadril
PT841939E (pt) Agentes terapeuticos e doencas auto-imunes
AU2003301744A1 (en) Fracture pin
ATE361756T1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4 protease
WO2000012047A3 (en) Enhancement of return to independent living status with a growth hormone secretagogue
CO4940453A1 (es) Nuevo metodo de tratamiento con agente antihiperglucemicos inhibidores de alfaglucosida- sa para tratamiento de diabetes